# Bioflow-DAPT Study

Study · id `cardio:ct-nct04137510` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04137510](<https://clinicaltrials.gov/study/NCT04137510>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04137510

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1948 participants.

## Technical summary

Registry record NCT04137510. Randomized; no masking; primary purpose treatment. Start 2020-02-24 (actual); primary completion 2022-09-20 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1948 participants (enrolled count; ClinicalTrials.gov record NCT04137510, source copy `cardio:ctgov-nct04137510-2024-06-07`, retrieved 2026-10-26)
- Started: 2020-02-24 (actual) (ClinicalTrials.gov record NCT04137510, source copy `cardio:ctgov-nct04137510-2024-06-07`, retrieved 2026-10-26)
- Primary completion: 2022-09-20 (actual) (ClinicalTrials.gov record NCT04137510, source copy `cardio:ctgov-nct04137510-2024-06-07`, retrieved 2026-10-26)
- Completion: 2022-09-20 (actual) (ClinicalTrials.gov record NCT04137510, source copy `cardio:ctgov-nct04137510-2024-06-07`, retrieved 2026-10-26)
- Countries: Australia; Austria; Belgium; Denmark; France; Germany; Hong Kong SAR China; Hungary; Italy; Latvia; Malaysia; Netherlands; New Zealand; Poland; Singapore; Spain; Switzerland; Thailand (ClinicalTrials.gov record NCT04137510, source copy `cardio:ctgov-nct04137510-2024-06-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04137510-2024-06-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Bioflow-DAPT Study
- Condition: Coronary Artery Disease
- Intervention (Device): Percutaneous coronary intervention
- Lead sponsor: Biotronik AG
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Biotronik AG (`cardio:org-biotronik-ag`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial (`cardio:pubmed-37624364`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Biodegradable polymer sirolimus-eluting or durable polymer zotarolimus-eluting stents in high bleeding-risk patients with acute coronary syndrome: the BIOFLOW-DAPT randomized trial (`cardio:pubmed-42555546`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 48fdb509fded3c097a911ce3f1379215d32b814c603b82fc12a112fcb45d8be8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
